• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • English 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Login
View Item 
  •   University of Thessaly Institutional Repository
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • View Item
  •   University of Thessaly Institutional Repository
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
All of DSpace
  • Communities & Collections
  • By Issue Date
  • Authors
  • Titles
  • Subjects

Early systemic sclerosis-opportunities for treatment

Thumbnail
Author
Sakkas, L. I.; Simopoulou, T.; Katsiari, C.; Bogdanos, D.; Chikanza, I. C.
Date
2015
DOI
10.1007/s10067-015-2902-5
Keyword
Classification
Criteria
Early systemic sclerosis
Immunosuppression
Treatment
INTERSTITIAL LUNG-DISEASE
PULMONARY ARTERIAL-HYPERTENSION
EULAR
SCLERODERMA TRIALS
GROWTH-FACTOR RECEPTOR
ORGAN INVOLVEMENT
STIMULATORY AUTOANTIBODIES
CLASSIFICATION CRITERIA
MYCOPHENOLATE-MOFETIL
RAYNAUDS-PHENOMENON
T-CELL
Rheumatology
Metadata display
Abstract
Systemic sclerosis (SSc) is characterized by microvasculopathy (Raynaud's phenomenon and fibrointimal proliferation), presence of autoantibodies and collagen deposition in skin (scleroderma) and internal organs. Microvasculopathy, detected by nailfold capillaroscopy, and disease-specific autoantibodies (anti-topoisomerase I, anti-centromere, anti-RNA polymerase III antibodies) usually appear earlier, even years before scleroderma. At that stage of the disease, immune activation with T cells and B cells promote fibrosis. Diagnosis of SSc has been relied on scleroderma, and by this time, internal organs may have developed fibrosis, a lethal feature with no available treatment. The new EULAR/ACR 2013 criteria for the classification of SSc will help identify SSc patients before fibrosis of internal organs. The early diagnosis of SSc, before the development of fibrosis in internal organs, will allow the introduction of immunosuppressive medications in these patients in a controlled setting (randomized trials). It is anticipated that this approach will change the hitherto grim prognosis of SSc for the better.
URI
http://hdl.handle.net/11615/32803
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [9728]
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister (MyDspace)
Help Contact
DepositionAboutHelpContact Us
Choose LanguageAll of DSpace
EnglishΕλληνικά
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013